Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma Retraction in /10.3892/ijo.2023.5485

Tang,Bo; Liang,Xingsi; Tang,Fang; Zhang,Jing; Zeng,Sien; Jin,Shengjian; Zhou,Lihua; Kudo,Yasusei; Qi,Guangying

doi:10.3892/ijo.2015.3214

Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma

Retraction in: /10.3892/ijo.2023.5485

Authors:
- Bo Tang
- Xingsi Liang
- Fang Tang
- Jing Zhang
- Sien Zeng
- Shengjian Jin
- Lihua Zhou
- Yasusei Kudo
- Guangying Qi
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Guilin Medical University, Affiliated Hospital, Guilin, Guangxi 541001, P.R. China , Department of Pathology, the Affiliated Hospital, Guilin Medical University, Guilin, Guangxi 541001, P.R. China, Department of Pathology and Physiopathology, Guilin Medical University, Guilin, Guangxi 541004, P.R. China, Department of Oral Molecular Pathology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima 770-8504, Japan
Published online on: October 20, 2015 https://doi.org/10.3892/ijo.2015.3214
Pages: 2208-2216

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor type, ranking as the third leading cause of all cancer-related deaths in the world. The post-surgical 5-year survival rate is low, largely due to the high recurrence rate. Therefore, the identification of target molecules that control the biological characteristics of HCC is of great importance. Ubiquitin-specific protease 22 (USP22) is a newly discovered deubiquitinating enzyme and is a cancer stem cell marker that plays a role in tumorigenesis, therapy resistance and cell cycle progression. Survivin is a member of the inhibitor of apoptosis protein (IAP) family and is known to function either as an inhibitor for apoptosis or as a regulator of cell division. Levels of survivin are correlated with the aggressiveness of tumors and a poor prognosis in various cancers including HCC. In the present study, we examined the USP22 expression and its association with survivin expression and clinicopathological features in HCC. First, we examined the expression of USP22 and survivin in 151 HCC cases by immunohistochemistry. High expression of USP22 and survivin was frequently observed in HCC cases, in comparison with normal adjacent liver tissues. Expression of USP22 and survivin was well correlated with malignant behavior including tumor size, stage and differentiation in HCC cases. Importantly, HCC patients with high expression of USP22 and survivin showed poor prognosis. USP22 expression was well correlated with survivin expression in HCC cases. This correlation was confirmed in HCC cell lines and tissues by RT-PCR and western blot analysis. Next, to investigate the biological role of USP22 in HCC, we examined the effect of USP22 knockdown on the cell growth and the expression of cell cycle-related protein including survivin in HCC cells. USP22 siRNA suppressed cell growth. Moreover, USP22 siRNA decreased survivin expression together with upregulation of CDK inhibitor, p21 and downregulation of cyclin B. These findings suggest that USP22 may be involved in HCC progression in cooperation with survivin. We suggest that USP22 can be useful as a new prognostic marker and therapeutic target in HCC patients.

View Figures

View References

1	El-Serag HB: Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology. 127(Suppl 1): S27–S34. 2004. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
3	Jin F, Xiang YB and Gao YT: Cancer survival in Shanghai, People's Republic of China. IARC Sci Publ. 145:37–50. 1998.
4	Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM and Baek KH: The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns. 6:277–284. 2006. View Article : Google Scholar
5	Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL and McMahon SB: The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 29:102–111. 2008. View Article : Google Scholar : PubMed/NCBI
6	Zhang XY, Pfeiffer HK, Thorne AW and McMahon SB: USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle. 7:1522–1524. 2008. View Article : Google Scholar : PubMed/NCBI
7	Liu Y, Yang Y, Xu H and Dong X: Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas. Diagn Mol Pathol. 19:194–200. 2010. View Article : Google Scholar : PubMed/NCBI
8	Zhang Y, Yao L, Zhang X, Ji H, Wang L, Sun S and Pang D: Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol. 137:1245–1253. 2011. View Article : Google Scholar : PubMed/NCBI
9	Tang B, Tang F, Li B, Yuan S, Xu Q, Tomlinson S, Jin J, Hu W and He S: High USP22 expression indicates poor prognosis in hepatocellular carcinoma. Oncotarget. 6:12654–12667. 2015. View Article : Google Scholar : PubMed/NCBI
10	Atanassov BS, Evrard YA, Multani AS, Zhang Z, Tora L, Devys D, Chang S and Dent SY: Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. Mol Cell. 35:352–364. 2009. View Article : Google Scholar : PubMed/NCBI
11	Atanassov BS and Dent SY: USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep. 12:924–930. 2011. View Article : Google Scholar : PubMed/NCBI
12	Uren AG, Pakusch M, Hawkins CJ, Puls KL and Vaux DL: Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc Natl Acad Sci USA. 93:4974–4978. 1996. View Article : Google Scholar : PubMed/NCBI
13	Yang D, Welm A and Bishop JM: Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA. 101:15100–15105. 2004. View Article : Google Scholar : PubMed/NCBI
14	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
15	Peters JM: The anaphase promoting complex/cyclosome: A machine designed to destroy. Nat Rev Mol Cell Biol. 7:644–656. 2006. View Article : Google Scholar : PubMed/NCBI
16	Li Z, Pei XH, Yan J, Yan F, Cappell KM, Whitehurst AW and Xiong Y: CUL9 mediates the functions of the 3M complex and ubiquitylates survivin to maintain genome integrity. Mol Cell. 54:805–819. 2014. View Article : Google Scholar : PubMed/NCBI
17	Connell CM, Colnaghi R and Wheatley SP: Nuclear survivin has reduced stability and is not cytoprotective. J Biol Chem. 283:3289–3296. 2008. View Article : Google Scholar
18	Glinsky GV: Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle. 4:1171–1175. 2005. View Article : Google Scholar : PubMed/NCBI
19	Glinsky GV, Berezovska O and Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 115:1503–1521. 2005. View Article : Google Scholar : PubMed/NCBI
20	Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, et al: Epigenetic stem cell signature in cancer. Nat Genet. 39:157–158. 2007. View Article : Google Scholar : PubMed/NCBI
21	Glinsky GV: Genomic models of metastatic cancer: Functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle. 5:1208–1216. 2006. View Article : Google Scholar : PubMed/NCBI
22	Sowa ME, Bennett EJ, Gygi SP and Harper JW: Defining the human deubiquitinating enzyme interaction landscape. Cell. 138:389–403. 2009. View Article : Google Scholar : PubMed/NCBI
23	Piao S, Ma J, Wang W, Liu Y, Zhang M, Chen H and Guo F, Zhang B and Guo F: Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma. Oral Oncol. 49:796–801. 2013. View Article : Google Scholar : PubMed/NCBI
24	Ning J, Zhang J, Liu W, Lang Y, Xue Y and Xu S: Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. Eur J Histochem. 56:e462012. View Article : Google Scholar
25	Piao S, Liu Y, Hu J, Guo F, Ma J, Sun Y and Zhang B: USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma. PLoS One. 7:e425402012. View Article : Google Scholar : PubMed/NCBI
26	Liu YL, Jiang SX, Yang YM, Xu H, Liu JL and Wang XS: USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys. 62:229–235. 2012. View Article : Google Scholar
27	Lin Z, Yang H, Kong Q, Li J, Lee SM, Gao B, Dong H, Wei J, Song J, Zhang DD, et al: USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell. 46:484–494. 2012. View Article : Google Scholar : PubMed/NCBI
28	Honda R, Körner R and Nigg EA: Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell. 14:3325–3341. 2003. View Article : Google Scholar : PubMed/NCBI
29	Beardmore VA, Ahonen LJ, Gorbsky GJ and Kallio MJ: Survivin dynamics increases at centromeres during G2/M phase transition and is regulated by microtubule-attachment and Aurora B kinase activity. J Cell Sci. 117:4033–4042. 2004. View Article : Google Scholar : PubMed/NCBI
30	Peroukides S, Bravou V, Alexopoulos A, Varakis J, Kalofonos H and Papadaki H: Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. Histol Histopathol. 25:299–307. 2010.PubMed/NCBI
31	Morinaga S, Nakamura Y, Ishiwa N, Yoshikawa T, Noguchi Y, Yamamoto Y, Rino Y, Imada T, Takanashi Y, Akaike M, et al: Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep. 12:1189–1194. 2004.PubMed/NCBI
32	Qi G, Kudo Y, Ando T, Tsunematsu T, Shimizu N, Siriwardena SB, Yoshida M, Keikhaee MR, Ogawa I and Takata T: Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B. Oral Oncol. 46:263–270. 2010. View Article : Google Scholar : PubMed/NCBI
33	Qi G, Tuncel H, Aoki E, Tanaka S, Oka S, Kaneko I, Okamoto M, Tatsuka M, Nakai S and Shimamoto F: Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep. 22:557–562. 2009.PubMed/NCBI
34	Tuncel H, Shimamoto F, Kaneko Guangying Qi H, Aoki E, Jikihara H, Nakai S, Takata T and Tatsuka M: Nuclear Aurora B and cytoplasmic survivin expression is involved in lymph node metastasis of colorectal cancer. Oncol Lett. 3:1109–1114. 2012.PubMed/NCBI
35	Hori M, Miki T, Okamoto M, Yazama F, Konishi H, Kaneko H, Shimamoto F, Ota T, Temme A and Tatsuka M: The detergent-soluble cytoplasmic pool of survivin suppresses anoikis and its expression is associated with metastatic disease of human colon cancer. PLoS One. 8:e557102013. View Article : Google Scholar : PubMed/NCBI
36	Acquati S, Greco A, Licastro D, Bhagat H, Ceric D, Rossini Z, Grieve J, Shaked-Rabi M, Henriquez NV, Brandner S, et al: Epigenetic regulation of survivin by Bmi1 is cell type specific during corticogenesis and in gliomas. Stem Cells. 31:190–202. 2013. View Article : Google Scholar
37	Bhattacharyya J, Mihara K, Ohtsubo M, Yasunaga S, Takei Y, Yanagihara K, Sakai A, Hoshi M, Takihara Y and Kimura A: Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression. Cancer Sci. 103:34–41. 2012. View Article : Google Scholar